Calidi Biotherapeutics Inc [AMEX: CLDI] closed the trading session at $0.20.
The stocks have a year to date performance of -86.42 percent and weekly performance of -6.82 percent. The stock has been moved at -91.16 percent over the last six months. The stock has performed -11.64 percent around the most recent 30 days and changed -66.56 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 1.25M shares, CLDI reached to a volume of 30246319 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Calidi Biotherapeutics Inc [CLDI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLDI shares is $2.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLDI stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Calidi Biotherapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 22, 2023. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on October 09, 2023, representing the official price target for Calidi Biotherapeutics Inc stock.
CLDI stock trade performance evaluation
Calidi Biotherapeutics Inc [CLDI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.82. With this latest performance, CLDI shares dropped by -11.64% in over the last four-week period, additionally sinking by -91.16% over the last 6 months – not to mention a drop of -98.01% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLDI stock in for the last two-week period is set at 43.86, with the RSI for the last a single of trading hit 44.69, and the three-weeks RSI is set at 42.53 for Calidi Biotherapeutics Inc [CLDI]. The present Moving Average for the last 50 days of trading for this stock 0.2820, while it was recorded at 0.2010 for the last single week of trading, and 1.8142 for the last 200 days.
Calidi Biotherapeutics Inc [CLDI]: An insightful look at the core fundamentals
Calidi Biotherapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.13 and a Current Ratio set at 0.13.
Calidi Biotherapeutics Inc [CLDI]: Institutional Ownership
The top three institutional holders of CLDI stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in CLDI stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in CLDI stock with ownership which is approximately 5.8386%.
